Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,972
  • Shares Outstanding, K 15,461
  • Annual Sales, $ 33,880 K
  • Annual Income, $ -26,940 K
  • EBIT $ -30 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.56
  • Price/Sales 1.21
  • Price/Cash Flow N/A
  • Price/Book 2.96

Options Overview Details

View History
  • Implied Volatility 440.99% ( +60.95%)
  • Historical Volatility 126.92%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 440.99% on 12/20/24
  • IV Low 17.14% on 10/11/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 30
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 3.76
  • Today's Open Interest 157
  • Open Int (30-Day) 95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +344,582.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +3.20%
on 12/19/24
5.14 -49.81%
on 11/25/24
-2.52 (-49.41%)
since 11/22/24
3-Month
2.50 +3.20%
on 12/19/24
7.50 -65.60%
on 10/09/24
-3.50 (-57.57%)
since 09/23/24
52-Week
2.05 +25.85%
on 04/17/24
8.19 -68.50%
on 01/26/24
-3.81 (-59.62%)
since 12/22/23

Most Recent Stories

More News
Nasdaq Futures Fall as Micron’s Sales Outlook Disappoints, U.S. GDP Data and Nike Earnings in Focus

September Nasdaq 100 E-Mini futures (NQU24) are trending down -0.23% this morning as an underwhelming sales forecast from chipmaker Micron weighed on sentiment, while investors awaited a flurry of U.S....

NQU24 : 19,808.01s (-0.21%)
MU : 89.60 (-0.58%)
FDX : 267.96 (-2.82%)
AAPL : 254.08 (-0.16%)
WHR : 114.75 (+0.21%)
MRNA : 39.46 (+0.18%)
NKE : 76.14 (-1.04%)
MKC : 77.92 (-1.19%)
WBA : 9.23 (-3.35%)
AYI : 302.86 (+0.05%)
HMB.S.DX : 149.550 (-0.60%)
LEVI : 17.31 (-0.46%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.57 (-2.97%)
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 2.57 (-2.97%)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 2.57 (-2.97%)
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.57 (-2.97%)
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

CASI : 2.57 (-2.97%)
CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 2.57 (-2.97%)
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.57 (-2.97%)
CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.57 (-2.97%)
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 2.57 (-2.97%)

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

3rd Resistance Point 2.93
2nd Resistance Point 2.88
1st Resistance Point 2.76
Last Price 2.57
1st Support Level 2.59
2nd Support Level 2.54
3rd Support Level 2.42

See More

52-Week High 8.19
Fibonacci 61.8% 5.84
Fibonacci 50% 5.12
Fibonacci 38.2% 4.40
Last Price 2.57
52-Week Low 2.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar